The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Year to date metric has recorded a gain of 15.61%.However, over the last six months, we can see a weaker performance of 18.34%. Over the last 30 days, the price of TSHA has fallen by 63.93%. And in the last five days, it has surged by 9.89%.
Taysha Gene Therapies Inc’s market performance has been unstable in recent times. The company’s stock hit a 1-year high of $4.32 on 06/13/24 and a low of $1.05 for the same time frame on 04/09/25.
52-week price history of TSHA Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Taysha Gene Therapies Inc’s current trading price is -53.70% away from its 52-week high, while its distance from the 52-week low is 90.48%. The stock’s price range during this period has varied between$1.05 and $4.32. The Taysha Gene Therapies Inc’s shares, which operate in the Healthcare, saw a trading volume of around 8.49 million for the day, a figure considerably higher than their average daily volume of 2.25 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Taysha Gene Therapies Inc (TSHA) has experienced a quarterly rise of 27.39% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 410.11M and boasts a workforce of 73 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.70, with a change in price of -0.56. Similarly, Taysha Gene Therapies Inc recorded 2,403,103 in trading volume during the last 100 days, posting a change of -21.87%.
TSHA’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for TSHA stands at 0.89. Similarly, the long-term debt-to-equity ratio is also 0.86.
TSHA Stock Stochastic Average
As of today, Taysha Gene Therapies Inc’s raw stochastic average for the last 50 days stands at 56.72%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 56.72%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 77.41% and 87.99%, respectively.
